vimarsana.com
  1. Home
  2. Live Updates
  3. Mark Svet - Breaking News

Latest Breaking News On - Mark svet - Page 1 : vimarsana.com

Data from New VOYAGER PAD Analyses at ACC 22 Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial.

United statesMark svetNone of the janssen pharmaceutical companiesAmerican heart associationAmerican college of cardiologyJanssen pharmaceuticals incDrug administrationJanssen research developmentUniversity of colorado anschutz school medicineJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionToolkit for health care professionalsCompanies of johnsonAmerican collegeAnnual scientific session

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.